Associations between serum vitamin D3, atherogenic indices of plasma and cardiometabolic biomarkers among patients with diabetes in the KERCADR study

Abstract

BackgroundWe sought the association between serum 25-hydroxyvitamin D3 (25(OH) D3) levels and atherogenic indices of plasma as novel predictive biomarkers of cardiometabolic disease risk in patients with type 2 diabetes mellitus (T2DM).MethodsThe present study was a nested case-control study conducted on 252 participants with T2DM and controls from the second phase of the KERCADR cohort study. The participants with a mean (±SD) age of 49.79 ± 5.85 years were randomly selected and allocated into case and control groups. Independent t-test, Hierarchical Linear Regression, Univariate ANOVA, and partial correlation were used for analysis the data. Atherogenic indices of plasma include Castelli Risk Index I (CRI I), Castelli Risk Index II (CRI II), and the novel Atherogenic Index of Plasma (AIP), and Atherogenic Coefficient (AC).ResultsThere was a significant difference among case and control groups for AIP in males and females (P < 0.001 and P = 0.007, respectively). The levels of AIP, CRI I, and AC significantly decreased (P = 0.017, P = 0.029, and P = 0.029, respectively) with improved serum vitamin D status only in control male participants. The main effect of BMI and vitamin D status on AIP, CRI I, and AC, and the main effect of BMI on CRI I, CRI II, and AC were significant in control males and females, respectively.ConclusionWe conclude that there is a reverse significant association between AIP and serum vitamin D among healthy males. Low serum level of vitamin D is associated with atherogenic dyslipidemia. Therefore, improving vitamin D status as an important indicator may alleviate AIP as a surrogate marker for predicting the risk of CVD events in healthy men and women with normal BMI.